Top Markets
Coin of the day
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rang in Aktien #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Aktienkurs
$2.70
Zuletzt synchronisiert: 2023-05-17
Marktkapitalisierung
$4.13M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Graybug Vision, Inc. (GRAY)

Kategorie

Kursverlauf für Graybug Vision, Inc. (GRAY)
Höchster Schlusskurs: $3.07 am 2023-05-01

Niedrigster Schlusskurs: $208.50 am 2020-09-01
Kursverlauf der Aktie von Graybug Vision, Inc. von 2020 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 -59.99%
2022 -72.75%
2021 -92.01%
2020 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE